Salicylihalamide A inhibits the V0 sector of the V-ATPase through a mechanism distinct from bafilomycin A1 - PubMed (original) (raw)
. 2004 May 7;279(19):19755-63.
doi: 10.1074/jbc.M313796200. Epub 2004 Mar 3.
Affiliations
- PMID: 14998996
- DOI: 10.1074/jbc.M313796200
Free article
Salicylihalamide A inhibits the V0 sector of the V-ATPase through a mechanism distinct from bafilomycin A1
Xiao-Song Xie et al. J Biol Chem. 2004.
Free article
Abstract
The newly identified specific V-ATPase inhibitor, salicylihalamide A, is distinct from any previously identified V-ATPase inhibitors in that it inhibits only mammalian V-ATPases, but not those from yeast or other fungi (Boyd, M. R., Farina, C., Belfiore, P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., and Bowman, E. J. (2001) J. Pharmacol. Exp. Ther. 297, 114-120). In addition, salicylihalamide A does not compete with concanamycin or bafilomycin for binding to V-ATPase, indicating that it has a different binding site from those classic V-ATPase inhibitors (Huss, M., Ingenhorst, G., Konig, S., Gassel, M., Drose, S., Zeeck, A., Altendorf, K., and Wieczorek, H. (2002) J. Biol. Chem. 277, 40544-40548). By using purified bovine brain V-pump and its dissociated V(1) and V(0) sectors, we identified the recognition and binding site for salicylihalamide to be within the V(0) domain. Salicylihalamide does not inhibit the ATP hydrolysis activity of the dissociated V(1)-ATPase but inhibits the ATPase activity of the holoenzyme by inhibiting the V(0) domain. Salicylihalamide causes a dramatic redistribution of cytosolic V(1) from soluble to membrane-associated form, a change not observed in cells treated with either bafilomycin or NH(4)Cl. By synthesizing and characterizing a series of salicylihalamide derivatives, we investigated the structural determinants of salicylihalamide inhibition in terms of potency and reversibility, and used this information to suggest a possible binding mechanism.
Similar articles
- Semisynthetic derivatives of concanamycin A and C, as inhibitors of V- and P-type ATPases: structure-activity investigations and developments of photoaffinity probes.
Dröse S, Boddien C, Gassel M, Ingenhorst G, Zeeck A, Altendorf K. Dröse S, et al. Biochemistry. 2001 Mar 6;40(9):2816-25. doi: 10.1021/bi001759q. Biochemistry. 2001. PMID: 11258892 - Total synthesis and initial structure-function analysis of the potent V-ATPase inhibitors salicylihalamide A and related compounds.
Wu Y, Liao X, Wang R, Xie XS, De Brabander JK. Wu Y, et al. J Am Chem Soc. 2002 Apr 3;124(13):3245-53. doi: 10.1021/ja0177713. J Am Chem Soc. 2002. PMID: 11916407 - Inhibitors of V-ATPases: old and new players.
Huss M, Wieczorek H. Huss M, et al. J Exp Biol. 2009 Feb;212(Pt 3):341-6. doi: 10.1242/jeb.024067. J Exp Biol. 2009. PMID: 19151208 Review. - Novel marine and microbial natural product inhibitors of vacuolar ATPase.
Beutler JA, McKee TC. Beutler JA, et al. Curr Med Chem. 2003 May;10(9):787-96. doi: 10.2174/0929867033457827. Curr Med Chem. 2003. PMID: 12678782 Review.
Cited by
- Molecular basis of V-ATPase inhibition by bafilomycin A1.
Wang R, Wang J, Hassan A, Lee CH, Xie XS, Li X. Wang R, et al. Nat Commun. 2021 Mar 19;12(1):1782. doi: 10.1038/s41467-021-22111-5. Nat Commun. 2021. PMID: 33741963 Free PMC article. - The binding site of the V-ATPase inhibitor apicularen is in the vicinity of those for bafilomycin and archazolid.
Osteresch C, Bender T, Grond S, von Zezschwitz P, Kunze B, Jansen R, Huss M, Wieczorek H. Osteresch C, et al. J Biol Chem. 2012 Sep 14;287(38):31866-76. doi: 10.1074/jbc.M112.372169. Epub 2012 Jul 19. J Biol Chem. 2012. PMID: 22815478 Free PMC article. - The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections.
Müller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, Kittel C, Samm E, Muller CP. Müller KH, et al. Br J Pharmacol. 2011 Sep;164(2):344-57. doi: 10.1111/j.1476-5381.2011.01346.x. Br J Pharmacol. 2011. PMID: 21418188 Free PMC article. - Disruption of the vacuolar-type H+-ATPase complex in liver causes MTORC1-independent accumulation of autophagic vacuoles and lysosomes.
Kissing S, Rudnik S, Damme M, Lüllmann-Rauch R, Ichihara A, Kornak U, Eskelinen EL, Jabs S, Heeren J, De Brabander JK, Haas A, Saftig P. Kissing S, et al. Autophagy. 2017 Apr 3;13(4):670-685. doi: 10.1080/15548627.2017.1280216. Epub 2017 Jan 27. Autophagy. 2017. PMID: 28129027 Free PMC article. - Reciprocal Regulation of V-ATPase and Glycolytic Pathway Elements in Health and Disease.
Hayek SR, Rane HS, Parra KJ. Hayek SR, et al. Front Physiol. 2019 Feb 15;10:127. doi: 10.3389/fphys.2019.00127. eCollection 2019. Front Physiol. 2019. PMID: 30828305 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources